Drug Approval | July 10, 2023
Astellas receives FDA priority review for Zolbetuximab biologics license application
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The VITA-FAST tokens have been met with overwhelming interest
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Subscribe To Our Newsletter & Stay Updated
